Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Post-Transplant Events

Elevated serum insulin-like growth factor binding protein-2 is associated with a high relapse risk after hematopoietic stem cell transplantation in childhood AML

Bone Marrow Transplantation volume 37, pages 589–594 (2006)Cite this article

Abstract

Insulin-like growth factor binding protein (IGFBP)-2 has mitogenic effects in normal and neoplastic cells. The purpose of this study is to examine the diagnostic and prognostic significance of elevated IGFBP-2 levels in children with AML after hematopoietic stem cell transplantation (HSCT) at relapse and continuous complete remission (CCR). In 27 children with AML (mean age 13.6±5.3 years; patients in remission n=15 with relapse n=12) serum parameters of IGFBP-2, IGFBP-3, IGF-I and IGF-II were analyzed up to 18 months after HSCT by RIA. AML-patients with evidence of relapse demonstrated a continuous increase of IGFBP-2 levels during the follow-up. At day 100 after HSCT, IGFBP-2 concentrations were significantly higher in patients with relapse than in children without relapse (7.4±4.0 standard deviation score (SDS) vs 3.9±1.7 SDS; P=0.01). Serum IGFBP-2 was identified as an independent factor for the prediction of relapse. Furthermore, the probability of relapse-free survival (RFS) in patients with IGFBP-2 >4.5 SDS at day 100 after HSCT was 31% compared to patients with IGFBP-2 <4.5 SDS was 72% (P=0.004). Patients with IGFBP-2 concentration up to 4.5 SDS more likely developed a relapse and had a poorer outcome. Identification of these patients allows a more individualized and aggressive adjuvant treatment and follow-up.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Creuzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93. J Clin Oncol 2001; 19: 2705–2713.

    Article  Google Scholar 

  2. Ortega JJ, Diaz de Heredia C, Olive T, Bastida P, Llort A, Armadan L et al. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy. Haematologica 2003; 88: 290–299.

    PubMed  Google Scholar 

  3. Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001; 97: 56–62.

    Article  CAS  Google Scholar 

  4. Creutzig U, Ritter J, Zimmermann M, Schellong G . Does cranial irritation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of childhood. AML Study-87. J Clin Oncol 1993; 11: 279–286.

    Article  CAS  Google Scholar 

  5. Loeb DM, Arceci RJ . What is the optimal therapy for childhood AML? Oncology (Huntington) 2002; 16: 1057–1066; discussion 1066, 1068–1070.

    Google Scholar 

  6. Lanvers C, Reinhardt D, Dubbers A . Pharmacology of all-trans-retinoic acid in children with acute promyelocytic leukemia. Med Pediatr Oncol 2003; 40: 293–301.

    Article  Google Scholar 

  7. Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Joudan E et al. Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol 2003; 78: 106–113.

    Article  CAS  Google Scholar 

  8. Busund LT, Richardsen E, Busund R, Ukkonem T, Bjornsen T, Busch C et al. Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol 2005; 58: 361–366.

    Article  CAS  Google Scholar 

  9. Kim HS, Ingermann AR, Tsubaki J, Twigg SM, Walker GF, Oh Y . Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells. Cancer Res 2004; 64: 2229–2237.

    Article  CAS  Google Scholar 

  10. Dupont J, Pierre A, Froment P, Moreau C . The insulin-like growth factor axis in cell cycle progression. Horm Metab Res 2003; 35: 740–750.

    Article  CAS  Google Scholar 

  11. Drop SL, Schuller AG, Lindenbergh-Kortleve DJ, Groffen C, Brinkman A, Zwarthoff EC . Structural aspects of the IGFBP family. Growth Regul 1992; 2: 69–79.

    CAS  PubMed  Google Scholar 

  12. Duan C, Xu Q . Roles of insulin-like growth factor (IGF) binding proteins in regulating IGF actions. Gen Comp Endocrinol 2005; 142: 44–52.

    Article  CAS  Google Scholar 

  13. Yu H, Nicar MR, Shi R, Berkeltt J, Nam R, Trachtenberg J et al. Levels of insulin-like growth factor-I (IGF-I) and IGF-binding proteins -2 and -3 in serial postoperative serum samples and risk of prostate cancer recurrence. Urology 2001; 57: 471–475.

    Article  CAS  Google Scholar 

  14. Elmlinger MW, Sanatani MS, Bell M, Dannecker GE, Ranke MB . Elevated insulin-like growth factor (IGF) binding protein (IGFBP)-2 and IGFBP-4 expression of leukemic T-cells is affected by autocrine/paracrine IGF-II action but not by IGF type I receptor expression. Eur J Endocrinol 1998; 138: 337–343.

    Article  CAS  Google Scholar 

  15. Lee EJ, Mircean C, Shmulevich I, Wang H, Liu J, Niemisto A et al. Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Mol Cancer 2005; 4: 7.

    Article  Google Scholar 

  16. Dawczynski K, Kauf E, Zintl F . Changes of serum factors (IGF-I,-II and IGFBP-2,-3) prior to and after stem cell transplantation in children with acute leukemia. Bone Marrow Transplant 2003; 32: 411–415.

    Article  CAS  Google Scholar 

  17. Blum WF, Breier BH . Radioimmunoassays for IGFs and IGFBPs. Growth Regul 1994; 4 (Suppl 1): 11–19.

    CAS  PubMed  Google Scholar 

  18. Blum WF, Horn N, Kratzsch J, Jorgensen JO, Juul A, Teale D et al. Clinical studies of IGFBP-2 by radioimmunoassay. Growth Regul 1993; 3: 100–104.

    CAS  Google Scholar 

  19. Frystyk J, Ivarsen P, Stoving RK, Dall R, Bek T, Hagen C et al. Determination of free insulin-like growth factor-I in human serum: comparison of ultrafiltration and direct immunoradiometric assay. Growth Horm IGF Res 2001; 11: 117–127.

    Article  CAS  Google Scholar 

  20. Cicognani A, Cacciari E, Pession A, Passini A, De Jasio R, Gennai M et al. Insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) concentration compared to stimulated growth hormone (GH) in the evaluation of children treated for malignancy. J Pediatr Endocrinol Metab 1999; 12: 629–638.

    Article  CAS  Google Scholar 

  21. Dorbyski WR . The role of allogeneic transplantation in high–risk acute myelogenous leukemia. Leukemia 2004; 18: 1565–1568.

    Article  Google Scholar 

  22. Knechtli CJ, Goulden NJ, Hancock JH, Harris EL, Garland RJ, Jones CG et al. Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia. Br J Haematol 1998; 102: 860–871.

    Article  CAS  Google Scholar 

  23. Sakatani T, Shimazaki C, Hirai H, Okano A, Hatsuse M, Okamoto A et al. Early relapse after high-dose chemotherapy rescued by tumor-free autologous peripheral blood stem cells in acute lymphoblastic leukemia: importance of monitoring of WT1 mRNA quantitatively. Leuk Lymphoma 2001; 42: 225–229.

    Article  CAS  Google Scholar 

  24. Dolmen G . Detection of minimal residual disease. Adv Cancer Res 2001; 82: 133–185.

    Article  Google Scholar 

  25. Ho PJ, Baxter RC . Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol 1997; 46: 333–342.

    Article  CAS  Google Scholar 

  26. Boulle N, Logie A, Gicquel C, Perin L, Le Bouc Y . Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab 1998; 83: 1713–1720.

    CAS  PubMed  Google Scholar 

  27. Petridou E, Skalkidou A, Dessypris N, Moustaki M, Mantzoros C, Spanos E et al. Insulin-like growth factor binding protein-3 predicts survival from acute childhood leukemia. Oncology 2001; 60: 252–257.

    Article  CAS  Google Scholar 

  28. Batron-Hay S, Boyle F, Ferrier A, Scott C . Elevated serum insulin-like growth factor binding protein-2 as a prognostic marker in patients with ovarian cancer. Clin Cancer Res 2004; 10: 1796–1806.

    Article  Google Scholar 

  29. Vorwerk P, Wex H, Hohmann B, Mohnike K, Schmidt U, Mittler U . Expression of components of the IGF signalling in childhood acute lymphoblastic leukaemia. Mol Pathol 2002; 55: 40–45.

    Article  CAS  Google Scholar 

  30. Cianfarani S, Rossi P . Neuroblastoma and insulin-like growth factor system. New insights and clinical perspectives. Eur J Pediatr 1997; 156: 256–261.

    Article  CAS  Google Scholar 

  31. Menouny M, Binox M, Babajako S . IGFBP-2 expression in a human cell line is associated with increased IGFBP-3 proteolysis, decrease IGFBP-1 expression and increased tumorgenicity. Int J Cancer 1998; 77: 874–879.

    Article  CAS  Google Scholar 

  32. Hettmer S, Dannecker L, Foell J, Elmlinger MW, Dannecker GE . Effects of insulin-like growth factors and insulin-like growth factor binding protein-2 on the in vitro proliferation of peripheral blood mononuclear cells. Hum Immunol 2005; 66: 95–103.

    Article  CAS  Google Scholar 

  33. Elmlinger MW, Sanatani MS, Bell M, Dannecker GE, Ranke MB . Elevated insulin-like growth factor (IGF) binding protein (IGFBP)-2 and IGFBp-4 expression of leukemic T-cells is affected by autocrine/paracrine IGF-II action but not by IGF type I receptor expression. Eur J Endocrinol 1998; 138: 337–343.

    Article  CAS  Google Scholar 

  34. Vorwerk P, Mohnike K, Wex H, Rohl FW, Zimmermann M, Blum WF et al. Insulin-like growth factor binding protein-2 at diagnosis of childhood acute lymphoblastic leukaemia and the prediction of relapse risk. J Clin Endocrinol Metab 2005; 90: 3022–3027.

    Article  CAS  Google Scholar 

  35. Bugie-Barhim S, Min HK, Oh Y . Potential of proteomics towards the investigation of the IGF-independent actions of IGFBP-3. Expert Rev Proteom 2005; 2: 71–86.

    Article  Google Scholar 

  36. Schutt BS, Langkamp M, Rauschnabel U, Ranke MB, Elmlinger MW . Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol 2004; 32: 859–868.

    Article  CAS  Google Scholar 

  37. Taya S, Inagaki N, Sengiku H, Makino H, Iwanatsu A, Urakawa I et al. Direct interaction of insulin-like growth factor-1 receptor with leukemia-associated RhoGEF. J Cell Biol 2001; 155: 809–820.

    Article  CAS  Google Scholar 

  38. Munker R, Salat C, Pihusch R, Diem H, Hiller E, Glass J et al. Levels of insulin-like growth factor after stem cell transplantation. Eur J Med Res 2001; 6: 181–184.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Friedrich-Schiller University of Jena, Jena, Germany

    K Dawczynski, E Kauf, D Schlenvoigt, B Gruhn, D Fuchs & F Zintl

Authors
  1. K Dawczynski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Kauf
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Schlenvoigt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B Gruhn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Fuchs
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F Zintl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K Dawczynski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dawczynski, K., Kauf, E., Schlenvoigt, D. et al. Elevated serum insulin-like growth factor binding protein-2 is associated with a high relapse risk after hematopoietic stem cell transplantation in childhood AML. Bone Marrow Transplant 37, 589–594 (2006). https://doi.org/10.1038/sj.bmt.1705281

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705281

Keywords

This article is cited by

Search

Advanced search

Quick links